2023
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
Tan W, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Nogueras-Gonzalez G, Navai N, Dinney C, Kamat A. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. European Urology Open Science 2023, 53: 16-22. PMID: 37441349, PMCID: PMC10334230, DOI: 10.1016/j.euros.2023.04.013.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder-sparing treatmentLong-term survival outcomesCancer-specific survivalBCG-unresponsive NMIBC patientsEarly radical cystectomyRadical cystectomySurvival outcomesOverall survivalBladder cancerDelayed RCNMIBC patientsEarly RCAnalysis of long-term survival outcomesHigh-grade recurrenceProgression-free rateRecurrence-free rateMedian follow-upShort-term outcomesLong-term outcomesCurrent smoker statusCT1 diseaseLymphovascular invasionVariant histologyPrimary endpoint
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapy